Anti-Gal antibody-mediated allograft rejection in alpha1,3-galactosyltransferase gene knockout mice: a model of delayed xenograft rejection.
BACKGROUND
The key role of anti-galactose alpha1,3-galactose (anti-alphaGal) xenoantibodies in initiating hyperacute xenograft rejection has been clearly demonstrated using a variety of in vitro and in vivo approaches. However, the role of anti-alphaGal antibodies in mediating post-hyperacute rejection mechanisms, such as antibody-dependent cellular cytoxicity, remains to be determined, primarily because of the lack of a small animal model with which to study this phenomena.


METHODS
Hearts from wild-type mice were transplanted heterotopically into alpha1,3-galactosyltransferase knockout (Gal KO) mice, which like humans develop antibodies to the disaccharide galactose alpha1,3-galactose (Gal). At the time of rejection, hearts were examined histologically to determine the mechanism of rejection.


RESULTS
Hearts from wild-type mice transplanted into high-titer anti-alphaGal recipients were rejected in 8-13 days. Histological examination demonstrated a cellular infiltrate consisting of macrophages (80-90%), natural killer cells (5-10%), and T cells (1-5%). In contrast, wild-type hearts transplanted into low anti-Gal titer recipients demonstrated prolonged (>90 day) survival. However, a significant proportion (30-40%) of these underwent a minor rejection episode between 10 and 13 days, but then recovered ("accommodated").


CONCLUSIONS
The results of this study suggest that the Gal KO mouse is a useful small animal vascularized allograft model, in which the role of anti-alphaGal antibody in graft rejection can be studied in isolation from other rejection mechanisms. The titer of anti-alphaGal antibody was found to be the critical determinant of rejection. The histopathological features of rejection in this model are very similar to other models of delayed xenograft rejection, in both the timing and composition of the cellular infiltrate. The Gal KO mouse therefore provides a new rodent model, which will aid in the identification of the distinct components involved in the pathogenesis of delayed xenograft rejection.
Pearse
M J
MJ
Immunology Research Centre, St Vincent's Hospital, Fitzroy, Australia.
Witort
E
E
Mottram
P
P
Han
W
W
Murray-Segal
L
L
Romanella
M
M
Salvaris
E
E
Shinkel
T A
TA
Goodman
D J
DJ
d'Apice
A J
AJ
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000913:Antibodies, Protozoan / Q000276:immunology; D004187:Disaccharides / Q000276:immunology*; D005260:Female; D005700:Galactosyltransferases / Q000235:genetics* / Q000378:metabolism; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D016027:Heart Transplantation / Q000276:immunology; D018320:Leishmania major / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009206:Myocardium / Q000473:pathology; D014183:Transplantation, Heterologous / Q000276:immunology*
D000906:Antibodies; D000913:Antibodies, Protozoan; D004187:Disaccharides; C055075:galactosyl-(1-3)galactose; D005700:Galactosyltransferases; C037959:beta-D-galactosyl-N-acetylglucosaminylglycopeptide alpha-1,3-galactosyltransferase